CN1279065A - Medicinal composition for treating dysmnesia and senile dementia - Google Patents
Medicinal composition for treating dysmnesia and senile dementia Download PDFInfo
- Publication number
- CN1279065A CN1279065A CN 99109457 CN99109457A CN1279065A CN 1279065 A CN1279065 A CN 1279065A CN 99109457 CN99109457 CN 99109457 CN 99109457 A CN99109457 A CN 99109457A CN 1279065 A CN1279065 A CN 1279065A
- Authority
- CN
- China
- Prior art keywords
- huperzine
- pharmaceutical composition
- preparation
- nasal
- senile dementia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000024827 Alzheimer disease Diseases 0.000 title claims abstract description 11
- 206010039966 Senile dementia Diseases 0.000 title claims abstract description 10
- 239000000203 mixture Substances 0.000 title abstract description 10
- ZQPQGKQTIZYFEF-WCVJEAGWSA-N Huperzine Natural products C1([C@H]2[C@H](O)C(=O)N[C@H]2[C@@H](O)C=2C=CC=CC=2)=CC=CC=C1 ZQPQGKQTIZYFEF-WCVJEAGWSA-N 0.000 claims abstract description 25
- 210000003928 nasal cavity Anatomy 0.000 claims abstract description 11
- 150000003839 salts Chemical class 0.000 claims abstract description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 19
- 238000002360 preparation method Methods 0.000 claims description 16
- ZRJBHWIHUMBLCN-SEQYCRGISA-N Huperzine A Natural products N1C(=O)C=CC2=C1C[C@H]1/C(=C/C)[C@]2(N)CC(C)=C1 ZRJBHWIHUMBLCN-SEQYCRGISA-N 0.000 claims description 15
- ZRJBHWIHUMBLCN-UHFFFAOYSA-N Shuangyiping Natural products N1C(=O)C=CC2=C1CC1C(=CC)C2(N)CC(C)=C1 ZRJBHWIHUMBLCN-UHFFFAOYSA-N 0.000 claims description 15
- 239000003814 drug Substances 0.000 claims description 15
- ZRJBHWIHUMBLCN-YQEJDHNASA-N huperzine A Chemical compound N1C(=O)C=CC2=C1C[C@H]1\C(=C/C)[C@]2(N)CC(C)=C1 ZRJBHWIHUMBLCN-YQEJDHNASA-N 0.000 claims description 15
- 239000000843 powder Substances 0.000 claims description 15
- ZRJBHWIHUMBLCN-BMIGLBTASA-N rac-huperzine A Natural products N1C(=O)C=CC2=C1C[C@@H]1C(=CC)[C@@]2(N)CC(C)=C1 ZRJBHWIHUMBLCN-BMIGLBTASA-N 0.000 claims description 15
- 229920000858 Cyclodextrin Polymers 0.000 claims description 11
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 9
- UBAPRWGDQPSCEH-UHFFFAOYSA-N Des-N-methyl-beta-obscurine Natural products N1CCCC2C3CC(C)CC21C(C=CC(=O)N1)=C1C3 UBAPRWGDQPSCEH-UHFFFAOYSA-N 0.000 claims description 7
- YYWGABLTRMRUIT-XHBSWPGZSA-N Huperzine B Natural products N1CCC[C@@H]2[C@@H]3C=C(C)C[C@]21C(C=CC(=O)N1)=C1C3 YYWGABLTRMRUIT-XHBSWPGZSA-N 0.000 claims description 7
- 229920002125 Sokalan® Polymers 0.000 claims description 6
- 229920002472 Starch Polymers 0.000 claims description 5
- 125000003118 aryl group Chemical group 0.000 claims description 5
- 239000008107 starch Substances 0.000 claims description 5
- 235000019698 starch Nutrition 0.000 claims description 5
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 4
- 229960001631 carbomer Drugs 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 229920000609 methyl cellulose Polymers 0.000 claims description 4
- 239000001923 methylcellulose Substances 0.000 claims description 4
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 3
- 150000001720 carbohydrates Chemical class 0.000 claims description 3
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 3
- 150000005846 sugar alcohols Chemical class 0.000 claims description 3
- 125000000217 alkyl group Chemical group 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 239000000890 drug combination Substances 0.000 claims description 2
- 239000004584 polyacrylic acid Substances 0.000 claims description 2
- 239000007923 nasal drop Substances 0.000 claims 1
- 239000007922 nasal spray Substances 0.000 claims 1
- 229940097496 nasal spray Drugs 0.000 claims 1
- 230000008901 benefit Effects 0.000 abstract description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 230000000694 effects Effects 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 5
- 229960000686 benzalkonium chloride Drugs 0.000 description 5
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 5
- 210000004556 brain Anatomy 0.000 description 5
- 239000012153 distilled water Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 4
- 241001597008 Nomeidae Species 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- NOOLISFMXDJSKH-UHFFFAOYSA-N p-menthan-3-ol Chemical compound CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 4
- 229960001685 tacrine Drugs 0.000 description 4
- YLJREFDVOIBQDA-UHFFFAOYSA-N tacrine Chemical compound C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 description 4
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 3
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 3
- 101150060184 ACHE gene Proteins 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 229940041616 menthol Drugs 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- WLAMNBDJUVNPJU-UHFFFAOYSA-N 2-methylbutyric acid Chemical compound CCC(C)C(O)=O WLAMNBDJUVNPJU-UHFFFAOYSA-N 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 229920001503 Glucan Polymers 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 208000026139 Memory disease Diseases 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- PIJVFDBKTWXHHD-UHFFFAOYSA-N Physostigmine Natural products C12=CC(OC(=O)NC)=CC=C2N(C)C2C1(C)CCN2C PIJVFDBKTWXHHD-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 230000002421 anti-septic effect Effects 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- 229940082484 carbomer-934 Drugs 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000001886 ciliary effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- -1 cyclic oligosaccharide Chemical class 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- TWNIBLMWSKIRAT-VFUOTHLCSA-N levoglucosan Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@H]2CO[C@@H]1O2 TWNIBLMWSKIRAT-VFUOTHLCSA-N 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229960001697 physostigmine Drugs 0.000 description 2
- PIJVFDBKTWXHHD-HIFRSBDPSA-N physostigmine Chemical compound C12=CC(OC(=O)NC)=CC=C2N(C)[C@@H]2[C@@]1(C)CCN2C PIJVFDBKTWXHHD-HIFRSBDPSA-N 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 229940124596 AChE inhibitor Drugs 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010051290 Central nervous system lesion Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 239000001116 FEMA 4028 Substances 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- UQOFGTXDASPNLL-XHNCKOQMSA-N Muscarine Chemical compound C[C@@H]1O[C@H](C[N+](C)(C)C)C[C@H]1O UQOFGTXDASPNLL-XHNCKOQMSA-N 0.000 description 1
- ALHUZKCOMYUFRB-OAHLLOKOSA-N Muscone Chemical compound C[C@@H]1CCCCCCCCCCCCC(=O)C1 ALHUZKCOMYUFRB-OAHLLOKOSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 208000035286 Spontaneous Remission Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229940086737 allyl sucrose Drugs 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical class OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 229960004853 betadex Drugs 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 229940116229 borneol Drugs 0.000 description 1
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229940025250 camphora Drugs 0.000 description 1
- 239000010238 camphora Substances 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 description 1
- 229940080345 gamma-cyclodextrin Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- ALHUZKCOMYUFRB-UHFFFAOYSA-N muskone Natural products CC1CCCCCCCCCCCCC(=O)C1 ALHUZKCOMYUFRB-UHFFFAOYSA-N 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 description 1
- 210000002850 nasal mucosa Anatomy 0.000 description 1
- 230000007830 nerve conduction Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- QTECDUFMBMSHKR-UHFFFAOYSA-N prop-2-enyl prop-2-enoate Chemical group C=CCOC(=O)C=C QTECDUFMBMSHKR-UHFFFAOYSA-N 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
A medicinal composition for treating dysmnesia and senile dementia by nasal cavity application contains transcutaneous huperzine or its similar, or the pharmaceutically receptable salt of transcutaneous huperzine or its similar and pharmaceutically receptable carrier. Its advantages include convenient application, high biological utilization rate and low by-effect.
Description
The present invention relates to a kind of pharmaceutical composition for the treatment of dysmnesia and senile dementia, especially for pharmaceutical composition that contains huperzine and analog thereof of nasal-cavity administration and preparation method thereof.
Serious day by day along with world's ageing phenomenon, benign memory deficits, and brain device matter dysmnesia and dull-witted, Alzheimer (Alzheimer ' s disease, AD) become senile common disease, more and more seriously endanger the healthy of people, also bring severe social problem.Existing studies show that, primary disease may make the damage of (Ach) nerve conduction because of brain neurotransmitter acetylcholine (Ach) level reduces, and causes the cholinergic system nonfunction, thereby dementia symptom such as dysmnesia occurs.Pass through to suppress the degraded of AchE with reversibility AchE inhibitor, thereby improve the level of Ach in the brain, treat senile dementia clinically and obtained effect preferably Ach.Relevant research report, with physostigmine, tacrine (tacrine), E2020 and huperzine are first-class comparatively detailed, and physostigmine has serious toxicity, and tacrine also has more serious hepatotoxicity, and this is restricted them in the use.And huperzine A has efficient selective to AchE in the brain, and the AchE at other position of health is not had effect; And different with tacrine and E2020, huperzine A can not cause the receptor of side effect in conjunction with the central nervous system, as muscarine M
1Receptor, M
2Receptor, this high selectivity make huperzine A to senile dementia and simple dysmnesia significant curative effect be arranged all, and side effect is seldom, but general spontaneous remission (Acta Pharmacologica Sinica, 12 (3), 250-252,1991).
The pharmacodynamics (Acta Pharmacologica Sinica, 1986,7:110-3) of the huperzine A injection that Wang Yue-e etc. have reported; The Orally administered composition of huperzine A is disclosed among the Chinese patent CN94103416.But because of the medication cycle of treatment dysmnesia and medicine for senile dementia longer, long term injections is brought very big inconvenience to the patient, and permanent oral patient's liver function is had adverse influence.Chinese patent CN95111588 discloses a kind of transcutaneous huperzing sticker, and to improve the comfort level of administration, but known owing to this area, this kind administering mode biology degree is low.So how both to have guaranteed its bioavailability, make things convenient for patient's long term administration again, alleviate its side effect, be a new problem.
Therefore, the purpose of this invention is to provide a kind of huperzine or its analog of containing, or the acceptable salt of medicine that forms of they and acid as active component pharmaceutical composition, said composition is suitable for passing through nasal-cavity administration, can guarantee the bioavailability of huperzine A, easy to use, less to the influence of human nasal ciliary movement.
The present invention also provides the preparation method of above-mentioned composition.
Pharmaceutical composition of the present invention is applicable to the treatment myasthenia gravis, Alzheimer (AD), and senile dementia and benign memory deficits, brain organic dysmnesia etc. also are used to prevent above-mentioned disease.
The huperzine of indication of the present invention and analog thereof have following structural formula (formula one):
R in the formula
1, R
2, R
3Can be respectively H or the low alkyl group that contains 1-7 carbon atoms.
The acceptable salt of pharmacy of the present invention can be the chemical compound and the organic acid of formula one, for example citric acid, oxalic acid, maleic acid, tartaric acid, benzoic acid, acetic acid, propanoic acid, benzenesulfonic acid, benzoic acid, methanesulfonic acid etc., it also can be the mineral acid example hydrochloric acid, hydrobromic acid, phosphoric acid, sulphuric acid, the salt that nitric acid etc. form.
The chemical compound of preferred formula one is huperzine A or huperzine B.
Pharmaceutical composition of the present invention also contains the medicine acceptable carrier except active component, as: cyclodextrin and/or other saccharide and/or sugar alcohol and/or aromatic and/or be selected from a kind of in starch, polyacrylic acid, carbomer (Carbomer), polyvinyl alcohol, methylcellulose and the derivant thereof.
" cyclodextrin " refers to the cyclic oligosaccharide that is linked by 6～12 glucose molecules, as α-, β-, γ-cyclodextrin and derivant thereof, preferably methylated β-cyclodextrin and derivant thereof.In prescription, cyclodextrin plays stabilizing agent, solubilizing agent, absorption enhancer.Other saccharide refers to disaccharides, and for example lactose, maltose, sucrose also refer to polysaccharide, glucosan for example, and mean molecule quantity is preferably 40,000 to 70,000 between 10,000 to 100,000." sugar alcohol " refers to mannitol and Sorbitol.Aromatic is that the olfactory sensation to the people has good stimulation, has the material of aromatic odor, as Oleum menthae, Mentholum, Borneolum Syntheticum (Borneolum Syntheticum), Camphora, muscone etc.Traditional medicine thinks that they have the effect of " causing resuscitation with aromatic drugs, refreshment do not have through not reaching "; They can promote Transdermal absorption the modern medicine proof.In this pharmaceutical composition, they can play fragrant seasoning, sorbefacient effect, and its consumption is about between 0.001 to 0.5%w/w.Starch refers to degradable starch.Methylcellulose and derivant thereof refer to methylcellulose, hydroxypropyl emthylcellulose etc.Carbomer means acrylic acid-allyl sucrose copolymer, is preferably carbomer 934, and molecular weight is 3 * 10
6About.
Compositions of the present invention can randomly use other this area can the conventional excipient that uses, and antiseptic for example is as benzalkonium chloride, bromo geramine, phenethanol etc.; Buffer agent is a phosphate buffer etc.; Isoosmotic adjusting agent such as sodium chloride etc.; PH regulator and viscosifier, antioxidant, cosolvent, surfactant, adhesive, emulsifying agent etc.Its consumption and addition manner can be implemented by this area routine techniques.
This pharmaceutical composition can be any form of pharmaceutically receptible energy by nasal-cavity administration, as being liquid (as Emulsion, solution, suspension, viscosity liquid), solid (as powder, microsphere), semi-solid (as gel) form.This pharmaceutical composition can be by any device of nasal-cavity administration that is suitable for as utilizing administrations such as dropper, suction pipe, aerosol apparatus or sponge ball.Can also utilize aerosol drug delivery, propellant can be selected for use as closing Chlorofluorocarbons (CFCs) (CFC), hydrofluorocarbon (HFC), carbon dioxide or other suitable gas.
Preparation can provide with single dose or multiple dose form.
Be noted that especially powder formulation demonstrates high bioavailability and advantages of excellent stability, and adding preservative agent not in the powder formulation, antiseptic can produce harm to the nasal cavity ciliary movement.
Preparation of drug combination of the present invention can adopt the pharmaceutical field known method.As the solution of preparation process, water separately, for example distilled water or pure water, or use ethanol preparation, also available water and physiology acceptable other solvents, for example mixed solvent of ethanol, propylene glycol, Polyethylene Glycol such as PEG400 preparation.
The preparation method of powder formulation is, at first preparation contains the solution of active component and excipient, vapors away solvent by lyophilization or other modes such as spray drying then, with this area routine techniques it is crushed to the powder of desired particle size then.At last,, obtain particle diameter, preferably between the granule of 50 to 100 μ m less than 100 μ m with the sieve in suitable aperture.
The pH value of pharmaceutical composition of the present invention should be preferably 5-7 in 4-7 scopes, be most preferably 5.5～6.5.
Pharmaceutical composition of the present invention, liquid, semi-solid form in this way, dosage is the each 0.05ml to 0.15ml in each nostril normally, and preferably each nostril is O.1ml.As be powder type, dosage is usually between 1mg to 15mg, preferably each nostril 5-10mg.Zoopery shows that huperzine A is t behind vein and nasal-cavity administration
1/2α is respectively 6.6min and 7.4min, t
1/2β is respectively 150 ± 53.0 and 180 ± 50.0min, and the bioavailability of nasal cavity applied medicine is about 98.3%.As seen after the administration of huperzine A via intranasal application, it is fast to play a role, and can guarantee its bioavailability.
So pharmaceutical composition advantage of the present invention is: by nasal-cavity administration, can overcome blood brain barrier, make medicine directly be delivered to the brain lesion place.In addition, because the nasal mucosa blood capillary is abundant, drug absorption is rapid, and directly enters the body circulation, no liver first-pass effect, its bioavailability is generally higher, can near or above injection system, thereby dosage is little.
Therefore, nasal administration composition of the present invention has easy to usely, is fit to long term administration, characteristics such as bioavailability height.
Following non-limiting example further specifies the present invention, and the preparation method among the embodiment is a preparation method general in this area.
Embodiment 1 huperzine liquid A prescription huperzine 30mg2,6-dimethyl-β-every 100ml solution of cyclodextrin 2.5g menthol 0.010g benzalkonium chloride 0.010gEDTA-Na 0.010g D-sorbite 2.0g distilled water 100ml contains huperzine 30mg
Embodiment 2 Huperzine B liquid A prescription huperzine 150mg2,6-dimethyl-β-every 100ml solution of cyclodextrin 2.50g menthol 0.010g benzalkonium chloride 0.010gEDTA-Na 0.010g D-sorbite 2.0g distilled water 100ml contains Huperzine B 150mg
Embodiment 3 huperzine gel A prescription huperzine 30mg2,6-dimethyl-β-cyclodextrin 1.50g benzalkonium chloride 0.01gEDTA-every 100ml gel of Na 0.1g D-sorbite 5g hydroxypropyl methylcellulose 1.5g pure water 100ml contains huperzine 30mg
Embodiment 4 huperzine gel B prescription huperzine 30mg β-every 100ml gel of cyclodextrin 1.50g polyvinyl alcohol 4g benzalkonium chloride 0.01g distilled water 100ml contains huperzine 30mg
The every 100ml gel of embodiment 5 Huperzine B gel A prescription Huperzine B 150mg carbomer 934 1.50g triethanolamine 1.0g menthol 0.01g distilled water 100ml contains Huperzine B 150mg
Embodiment 6 powders A prescription huperzine A 30mg2,6 dimethyl-β-every 10g powder of cyclodextrin 4.4g mannitol 5.57g contains huperzine A 0.030g
The every 10g powder of embodiment 7 powder B prescription huperzine A 30mg glucosan (mean molecule quantity 70,000) 9.97g contains huperzine A 30mg
Embodiment 8 powder C prescription huperzine 30mg β-every 10g powder of cyclodextrin 0.5g lactose 9.47g contains huperzine 30mg
The every 10g powder of embodiment 9 powder D prescription huperzine 30mg borneol 0.10g sucrose 9.87g contains huperzine 30mg
Embodiment 10 microballoons prescription huperzine 30mg degradable starch 10.0g adding distil water to the every 10g spherex of 100ml freeze drying contains huperzine 30mg
Claims (8)
1, a kind of pharmaceutical composition that is used for nasal-cavity administration treatment dysmnesia disease and senile dementia, contain huperzine or its analog and/or the acceptable salt of its medicine and the medicine acceptable carrier of following structural:
R in the formula
1, R
2, R
3Can be respectively H or the low alkyl group that contains 1-7 carbon atoms.
2, pharmaceutical composition as claimed in claim 1, described huperzine are huperzine A or huperzine B.
3, pharmaceutical composition as claimed in claim 1, described huperzine are huperzine A.
4, pharmaceutical composition as claimed in claim 1, its preparation are the dry powder nasal spray preparation.
5, pharmaceutical composition as claimed in claim 1, its preparation are the nasal drop body preparation.
6, pharmaceutical composition as claimed in claim 1, described medicine acceptable carrier are cyclodextrin or derivatives thereof and/or other saccharide and/or sugar alcohol and/or aromatic and/or are selected from starch, polyacrylic acid, carbomer, polyvinyl alcohol, methylcellulose or derivatives thereof.
7, preparation of drug combination method as claimed in claim 1 is characterized in that active component is prepared mutually with the medicine acceptable carrier.
8, pharmaceutical composition as claimed in claim 1 is the medicine as nasal-cavity administration treatment dysmnesia disease and senile dementia.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 99109457 CN1279065A (en) | 1999-07-06 | 1999-07-06 | Medicinal composition for treating dysmnesia and senile dementia |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 99109457 CN1279065A (en) | 1999-07-06 | 1999-07-06 | Medicinal composition for treating dysmnesia and senile dementia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1279065A true CN1279065A (en) | 2001-01-10 |
Family
ID=5273928
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 99109457 Pending CN1279065A (en) | 1999-07-06 | 1999-07-06 | Medicinal composition for treating dysmnesia and senile dementia |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1279065A (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003004024A1 (en) * | 2001-07-03 | 2003-01-16 | Shandong Luye Pharmaceutical Co., Ltd. | Injectable sustained-release microspheres of huperzine a compounds |
| WO2006056129A1 (en) * | 2004-11-26 | 2006-06-01 | Delong Xie | Compositions of huperzia serrata alkaloids comprising huperzine a and huperzine b and preparation thereof |
| EP1977735A1 (en) | 2003-03-14 | 2008-10-08 | Debio Recherche Pharmaceutique S.A. | Subcutaneous delivery system, process for the preparation of the same and use of the same for the treatment of cholinergic deficient disorders |
| CN101244026B (en) * | 2007-02-14 | 2011-03-16 | 中国科学院上海药物研究所 | Huperzine and its derivant or its salt implantation agent, its preparation method and application |
| CN1961879B (en) * | 2005-11-09 | 2011-11-30 | 上海医药工业研究院 | Pharmaceutical composition for nose administered in-situ gel spray of Huperzine A, preparation process and use thereof |
| CN103386005A (en) * | 2012-05-12 | 2013-11-13 | 石家庄以岭药业股份有限公司 | Application of traditional Chinese medicinal composition in preparation of medicines for treating study and memory disorders |
-
1999
- 1999-07-06 CN CN 99109457 patent/CN1279065A/en active Pending
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003004024A1 (en) * | 2001-07-03 | 2003-01-16 | Shandong Luye Pharmaceutical Co., Ltd. | Injectable sustained-release microspheres of huperzine a compounds |
| DE10297018B4 (en) * | 2001-07-03 | 2010-01-28 | Shandong Luye Pharmaceutical Co., Ltd., Yantai City | Depot microspheres for the injection of huperzine A compounds |
| EP1977735A1 (en) | 2003-03-14 | 2008-10-08 | Debio Recherche Pharmaceutique S.A. | Subcutaneous delivery system, process for the preparation of the same and use of the same for the treatment of cholinergic deficient disorders |
| WO2006056129A1 (en) * | 2004-11-26 | 2006-06-01 | Delong Xie | Compositions of huperzia serrata alkaloids comprising huperzine a and huperzine b and preparation thereof |
| US8574633B2 (en) | 2004-11-26 | 2013-11-05 | Delong Xie | Huperzia serrata (Thunb.) Trev. composition comprising compounded Huperzine A and Huperzine B and methods for preparing it |
| CN1961879B (en) * | 2005-11-09 | 2011-11-30 | 上海医药工业研究院 | Pharmaceutical composition for nose administered in-situ gel spray of Huperzine A, preparation process and use thereof |
| CN101244026B (en) * | 2007-02-14 | 2011-03-16 | 中国科学院上海药物研究所 | Huperzine and its derivant or its salt implantation agent, its preparation method and application |
| CN103386005A (en) * | 2012-05-12 | 2013-11-13 | 石家庄以岭药业股份有限公司 | Application of traditional Chinese medicinal composition in preparation of medicines for treating study and memory disorders |
| CN103386005B (en) * | 2012-05-12 | 2017-08-25 | 石家庄以岭药业股份有限公司 | A kind of application of Chinese medicine composition in the medicine for preparing treatment learning memory disorder |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5705520A (en) | Medicaments | |
| EP1059942B1 (en) | Pharmaceutical compositions containing cyclodextrins and taxoids | |
| CN1145486C (en) | Pharmaceutical compositions containing eletriptan hemisulphate and caffeine | |
| CN100423709C (en) | Pharmaceutical composition for intranasal delivery comprising fentanyl | |
| JP2002363097A (en) | Stabilized and lyophilized type pharmaceutical composition | |
| JP5103018B2 (en) | Intranasal composition | |
| CN101264058B (en) | Huperzine A and its derivative or salts sustained-release nanometer granule and preparing method thereof | |
| CN1279065A (en) | Medicinal composition for treating dysmnesia and senile dementia | |
| CN1882313A (en) | Menthol solutions of drugs | |
| CN106361700A (en) | Nalmefene hydrochloride nasal medicine administration preparation | |
| EP3556349B1 (en) | Parenteral liquid preparation comprising carbamate compound | |
| CN1400892A (en) | Pharmaceutical composition for intramuscular injection containing loxoprofen | |
| EP1707195A1 (en) | Retinoic acid-containing remedy for diabetes | |
| WO2025113679A1 (en) | Pharmaceutical composition, preparation and metolazone lyophilized powder preparation, and preparation methods therefor and uses thereof | |
| KR101992585B1 (en) | Intravenous antiviral treatments | |
| WO2007147373A2 (en) | Pharmaceutical composition for injectional, particularly targeted local administration | |
| JP4372398B2 (en) | External preparation for free radical disease | |
| CN1200710C (en) | New use of a macrolide compound | |
| CN108938653B (en) | Application of oxidized 1, 4-beta-D-glucuronic acid oligosaccharide in preparation of medicine for treating Alzheimer disease | |
| CZ20001636A3 (en) | Pharmaceutical preparations containing cyclodextrins and taxoids | |
| JP2000191546A (en) | Antitumor agent | |
| CN1832725A (en) | Biologically active compositions containing triazines | |
| HK1017987A (en) | The pharmacological use of certain cystine derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |